Status:
RECRUITING
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Lead Sponsor:
Fudan University
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor t...
Eligibility Criteria
Inclusion
- Age at least 18 years.
- Pathologically confirmed diagnosis of a solid tumor cancer.
- Patients receiving treatment with immune checkpoint inhibitors.
- Ability to understand and willingness to provide the informed consent.
Exclusion
- Age \< 18 years.
- Patients with hematological malignancies or solid benign tumors.
- Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04766515
Start Date
September 1 2020
End Date
August 31 2025
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, China